Research indicates that NXT USA’s proprietary formulation Digexin addresses various types of gastrointestinal (GI) issues in adults prescribed GLP-1 receptor agonist therapy.
The company says that at least half of GLP-1 patients experience GI side effects. In some cases, this discomfort has prompted class-action lawsuits against drug manufacturers.
Digexin features a proprietary blend of okra fruit (Abelmoschus esculentus) and ashwagandha root (Withania somnifera).
These botanicals synergistically support gut health through complementary mechanisms. Okra’s soothing polysaccharides coat and hydrate the intestinal lining, promoting smoother transit. Meanwhile, ashwagandha root helps the body recalibrate stress responses by reducing cortisol and supporting serotonin production.
NXT USA says this dual action targets the “interplay between stress and digestion” — helping normalize bowel rhythms, reduce discomfort, and restore balance in seven days.
Eric Anderson, managing director of NXT USA, says these results support Digexin’s potential to complement GLP-1 drugs as it helps to reduce side effects and supports overall well-being.
“As GLP-1 use grows worldwide, there is a clear need for supportive solutions that enhance patient comfort and compliance. Digexin’s bidirectional action on the gut and brain makes it uniquely suited to this role.”
Improvements in sleep quality and stress
The open-label study included patients experiencing various GI side effects who were taking oral semaglutide, the generic name for GLP-1 drugs like Ozempic or Rybelsus.
For three weeks, the subjects supplemented with Digexin and researchers monitored them for changes in GI comfort and overall well-being.
Participants reported “meaningful improvements” in digestive comfort and function, including reductions in constipation, reflux, and swallowing difficulties. They also had more regular and complete bowel movements.
Beyond digestive outcomes, subjects taking Digexin also experienced improvements in sleep quality, reduced perceived stress, and “greater overall quality of life.” The supplement was well tolerated, and no adverse events were reported.
“We are not about activating GLP-1 activity,” says Anderson. “Digexin addresses GLP-2 — as in No. 2. That is, constipation that results from dieting strategies. Our research is built on rigorous, reproducible human clinical trials designed for real-world application. Digexin delivers results that consumers can trust and brands can build on.”
The preliminary findings have been submitted for peer-review publication.
Opportunities to innovate around GLP-1
NXT USA highlights that some new health supplement launches, like those with fiber-based ingredients, claim to modulate GLP-1 levels in a similar way that the pharmaceuticals do. Last month, scientists discovered specific bacteria that naturally produce GLP-1, which may aid fat loss and blood sugar regulation.
While some nutraceuticals claim to work on the GLP-1 pathway, none of these products can precisely replicate the results from semaglutide, the active ingredient of these medications.
However, NXT USA underscores the commercial opportunity for supplements that help patients manage drug side effects. Recent launches have capitalized on the popularity of GLP-1 weight loss by addressing the various side effects from these medications.
Brightseed recently launched BioMetaControl, a metabolic health ingredient based on bioactives identified through the company’s proprietary AI platform, Forager. It claims to support glucose control, sustained energy, and digestive relief, which are common needs among GLP-1 users.
Last month, Danone’s brand Oikos introduced Oikos Fusion, the “first and only” yogurt drink in the US designed to support muscle retention for these consumers. And earlier this year, PanTheryx launched its patented supplement, Relesium, which was clinically shown to alleviate the GI side effects from GLP-1 drugs.
Nutrition Insight hosted a webinar featuring experts from ADM, which expanded on the significant opportunity for food and nutrition brands to serve this growing consumer group with complementary products.
